Tranexamic acid and traumatic brain injuries
Katarina Sanford1, Sarah Garcia
1At the time this article was written, Katarina Sanford was a student in the PA program at the University of St. Francis in Albuquerque, N.M. Sarah Garcia is pharmacotherapeutics course director at the University of St. Francis. The authors have disclosed no potential conflicts of interest, financial or otherwise.
JAAPA : Official Journal of the American Academy of Physician Assistants
|November 25, 2020
Abstract:
The CRASH-3 trial examined the use of tranexamic acid (TXA) in patients with intracranial bleeding secondary to traumatic brain injury. The trial demonstrated that TXA, an antifibrinolytic medication, reduces mortality in patients with mild to moderate head injuries. However, because of the trial's multiple limitations, TXA cannot yet be called the gold standard.
